TO · FRX.TO
Fennec Pharmaceuticals Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Research Triangle Park, NC 27709
- Website
- fennecpharma.com
Price at previous close
$13.69
Market cap 396.69M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $0.63 | ||||
| 2012 | $2.55 | ||||
| 2013 | $2.82 | ||||
| 2014 | $3.35 | ||||
| 2015 | $2.16 | ||||
| 2016 | $3.21 | ||||
| 2017 | $11.91 | ||||
| 2018 | $8.63 | ||||
| 2019 | $10.24 | ||||
| 2020 | $9.51 | ||||
| 2021 | $6.92 | $47.47 | |||
| 2022 | $12.63 | $0.00 | $0.00 | ||
| 2023 | $13.20 | $255.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $9.82 | $362.59 | $63,244.64 | $0.00 | $0.00 |
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
- CEO
- Jeffrey S. Hackman
- Employees
- 32
- Beta
- 0.91
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $13.69) − 1 = — (DCF, example).